MedTrace Logo

Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France

NCT03334019 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 559

Last updated 2018-05-30

No results posted yet for this study

Summary

Diseases naturally transmitted between animals and humans (zoonoses) are one of the leading causes of emergence or re-emergence of human infectious diseases. Non-foodborne zoonoses are commonly transmitted to human directly by contact with infected animals or contaminated environment. People working with animals such as farmers and veterinarians are particularly at risk of infection. Some zoonoses can also be transmitted indirectly thought the air and therefore can affect the general population. Example is Q fever, a disease caused by Coxiella burnetii, a bacterium highly resistant in the environment.

In Western France, Q fever is endemic in cattle herds. To improve human zoonotic disease surveillance, the investigators will conduct a population based study in this area.

The aims of the study are:

1. To assess seroprevalence of Coxiella burnetii infection among general population, farmers and veterinarians in Western France
2. To identify risk factors for Coxiella burnetii seropositivity in these populations

Conditions

  • Q Fever

Interventions

OTHER

blood test

Data collected on general population, farmers and veterinarians though questionnaires and blood samples.

Sponsors & Collaborators

  • ONIRIS

    collaborator INDUSTRY

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Leila Moret, PU-PH · Nantes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2018-05-05
Completion
2019-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334019 on ClinicalTrials.gov